Profitelligence Profitelligence · Filing Ledger Open BDX research →

Form 8-K · Current Report · Filed 2026-07-22

Dr. Michael Garrison to Retire from BD

On July 19, 2026, Dr. Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments at Becton, Dickinson and Company (BD), announced his intention to retire effective October 2, 2026. Dr. Garrison will remain in his role through the end of the fiscal year to ensure a smooth transition. A comprehensive search is underway to identify the next President of the Medical Essentials segment. Additionally, the BioPharma Systems segment will report directly to Thomas E. Polen, Chairman, CEO, and President of BD, streamlining the company's operating model.

Filer
Becton, Dickinson and Company BDX · NYSE
Filed
Accession
0001628280-26-049103
CIK
0000010795
Signal
High impactHealthcare

Items reported

Item events

Reported Item

CEO Resignation Key Executive Departure New CEO Appointed Key Executive Appointment Regulatory Investigation

Market reaction

Close before filing

$153.84

Next session

-0.6%

Since filing

+7.7%

Latest close

$165.62

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from BDX reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, BDX insiders reported 6 Form 4 transactions — net selling of $350K.

Full BDX insider history →

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.

Exchange NYSE Industry Medical Instruments & Supplies Company website ↗

Never miss another BDX filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts